The KDIGO 2024 CKD treatment guideline aligns with its earlier diabetes guidance by recommending long-acting GLP-1 RA in T2D patients with CKD who are obese and require further glycemic control or cardioprotection beyond standard therapy (metformin and SGLT2 inhibitors) [7]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.